ICE Biopharma has 2 core businesses: in-licensing specialty and rare disease drugs for Europe and Canada, and operational consultancy to companies evaluating international Commercialization options. We want European and Canadian patients to have access to the breakthrough therapies they deserve.
Products, services, technology
As Operational Consultants, we advise Biotechs on international launch options, identifying the best go-to-market strategy and helping execute key pre-Approval activities. As licensee, we commercialize late-stage therapeutics for rare and specialty indications for the European and Canadian markets.
Cooperation possibilities
ICE Biopharma: partner of choice for innovative Biotechs evaluating international Commercialization. With multiple launch experience, we advise on go-to-market strategy and execution, enabling partners to fulfil their mission to patients, build enterprise value and preserve strategic optionality.
- https://icebiopharma.com/
- +41 79 592 23 17
- Send an email
- Francis Marsland
Some insights
By enabling successful launches, we ensure that European and Canadian patients have access to the innovative therapeutics they deserve.
Our core strengths are business development, licensing and commercialisation of high technology therapeutics.
We advise innovative biotechnology companies on international commercialisation and in license novel therapeutics for specialty and rare diseases.
The Swiss biotech ecosystem is a rich source of key talents and an emerging center for later-stage therapeutic development. It is also a great forum for business development and collaboration.
Biotech executives with late-stage or in-market therapeutics assets who want to evaluate their commercialization options internationally.
